The present disclosure relates to an aqueous composition of an antifungal peptide, to methods of treatment using the composition and to uses of the composition.

A pulmonary delivery system includes an elongated body having an openable and closeable portion thereof for receiving an insertable and replaceable container such as a cartridge of pure medical product disposed in a saline solution. The medical product may be epinephrine, insulin or nicotine disposed in a saline solution. The system also incorporates a penetrating element that is disposed in the cylinder to pierce the cartridge and release the nicotine solution into the cylinder and into or on a micron mesh grid. A flow of air created by inhaling through a mouthpiece draws air into an individual's lungs from an entrainment port and onto a grid for atomizing a mist of micron droplets through the grid. It is recognized that the air from the entrainment port further dilutes the concentration of the medical product. The grid is connected to a source of electrical power to vibrate the mesh grid.

Provided is a composition of antiviral agent for use in prophylaxis or treatment against pathogenic infection. The liposomal antiviral agent of the composition has a liposome and an antiviral agent entrapped in the liposome. The antiviral agent has been stably encapsulated in the liposome, and the resulting liposomal antiviral agent is proven to be stably aerosolized or nebulized for administration via the inhalation route to treat a subject in need thereof with reduced side effect.

The present invention provides, among other things, improved methods and pharmaceutical compositions for treating cystic fibrosis based on codon optimized mRNA encoding a wild-type Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein.

The present invention relates to methods, compounds, and compositions for treating viral infections, including COVID-19 viral infections. In certain embodiments, the compositions comprise: i) a remdesivir analog, ii) remdesivir or a remdesivir analog, and a surfactant, a cyclodextrin, or a combination thereof, iii) nanoparticles comprising albumin and remdesivir or remdesivir analog, iv) liposomes comprising lipids and remdesivir or remdesivir analog; and/or v) microparticles comprising PLA and/or PLGA, and remdesivir or remdesivir analog. In certain embodiments, the compositions are aqueous (e.g., for intravenous administration). In other embodiments, the compositions are nebulized or in the form of a dry powder (e.g., for inhalation by an infected subject).

Provided herein are methods of using voclosporin for treating or preventing coronavirus infection, particularly in subjects that require immunosuppression.

The present invention provides a composition for relief or management of a pain associated with a disorder, e.g., joint or skeletal condition, the composition comprises n effective amount of retinoic acid. Methods of making and using the same are also disclosed.

Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.

Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.